Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor

We demonstrate multiple DC defects in patients with brain tumors. This includes a profound reduction in the frequency of multiple DC subsets, diminished activation marker expression, and reduced Flt3L levels in cancer patients with brain tumors compared to those without. We also demonstrate reduced intra-tumoral DCs in brain compared to lung tumors. This is the first time DC subsets have been fully characterized in a range of brain tumor patients. Importantly, corticosteroid usage was closely associated with DC defects, highlighting the adverse effects of a standard symptomatic treatment on these critical immune cells. However, tumors located within the brain also directly contribute to DC defects. Finally, we identified several mouse brain tumor models that replicate key observations in patients and may be used to further understand this endogenous DC deficiency and to develop approaches to restore DCs, ultimately leading to new combination immunotherapies for the treatment of brain cancers.

Authors

Institutions

Publication Details

Journal
iScience
Published
2026-02-26
DOI
https://doi.org/10.1016/j.isci.2026.115160
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor

Melinda Nay Tea, Chloé Shard, Eunwoo Nam, Santosh Poonnoose et al.
iScience
Immunotherapy and Immune Responses
article

Tumors located in the brain impair the frequency and phenotype of dendritic cells in blood and tumor

Melinda Nay Tea, Chloé Shard, Eunwoo Nam, Santosh Poonnoose, Stuart Maxwell Pitson, Briony L. Gliddon, Sakthi Lenin, Shaheen Khan, Katherine A. Pillman, Lisa M. Ebert, Bryan Gardam, Rebecca J. Ormsby, Anupama Pasam, Tessa Gargett, Julie M Bracken, Michael P. Brown, Shahneen Sandhu, Guillermo A. Gomez
article en

Abstract

We demonstrate multiple DC defects in patients with brain tumors. This includes a profound reduction in the frequency of multiple DC subsets, diminished activation marker expression, and reduced Flt3L levels in cancer patients with brain tumors compared to those without. We also demonstrate reduced intra-tumoral DCs in brain compared to lung tumors. This is the first time DC subsets have been fully characterized in a range of brain tumor patients. Importantly, corticosteroid usage was closely associated with DC defects, highlighting the adverse effects of a standard symptomatic treatment on these critical immune cells. However, tumors located within the brain also directly contribute to DC defects. Finally, we identified several mouse brain tumor models that replicate key observations in patients and may be used to further understand this endogenous DC deficiency and to develop approaches to restore DCs, ultimately leading to new combination immunotherapies for the treatment of brain cancers.

iScienceVol. 29(3)
Royal Adelaide Hospital (AU), The University of Melbourne (AU), Flinders University (AU), Peter MacCallum Cancer Centre (AU), Flinders Medical Centre (AU), SA Health (AU), Centre for Cancer Biology (AU), The University of Adelaide (AU)
Openalex Percentile: Top 41%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.